SGLT-2抑制剂和GLP-1受体激动剂的联合使用_替代终点和硬终点的潜在好处.pdf,1879 Send Orders for Reprints to reprints@benthamscience.ae Current Pharmaceutical Design, 2018, 24, 1879-1886 REVIEW ARTICLE Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agoni
2型糖尿病;心血管事件;钠葡萄糖协同转运蛋白2抑制剂;胰高血糖素样肽-1受体激动剂 Research advance in SGLT2 inhibitor combined with GLP-1 receptor agonist in the treatment of type 2 diabetes with cardiovascular disease ZHAO Zhe, YANG Dandan, ZHAN Xiaorong (Third Department of Endocrinology, First ...
例如,在 2021 年 2 月前,唯一可用的 SGLT2抑制剂恩格列净需满足特定标准才能使用,GLP-1 RA 司美格鲁肽则需要药剂师预先授权。 面对这种情况,为改善患者治疗效果,VAAAHS 的研究人员开展了一项质量改进(QI)干预研究。该研究成果发表在《BMC Primary Care》上。 研究人员开展此项研究时,主要采用了以下关键技术方法...
27. Fu EL, Mastrorilli J, Bykov K, et al.. A population-based cohort defined risk of hyperkalemia after initiating SGLT-2 inhibitors, GLP1 receptor agonists or DPP-4 inhibitors to patients with chronic kidney disea...
the cellular mechanisms associated with CV protection afforded by these agents, investigating a pleiotropic range of potential effects to improve bone marrow (BM), kidney, heart, and vascular health. Additionally, there is gr...
以下药物的使用可以显著减轻1型糖尿病患者的体重:GLP-1受体激动剂利拉鲁肽 0.6mg可平均减重-2.22kg,1.2mg可平均减重-3.74kg,1.8mg可平均减重-4.85kg;SGLT-2抑制剂恩格列净2.5mg平均减重-1.47kg,10mg平均减重-2.77kg,25mg平均减重-3.06kg;索他列净200mg平均减重-2.40kg,400mg平均减重-3.23kg。其他药物和生活方...
Use of GLP-1 receptor agonists was associated with a lower rate of hyperkalemia than DPP-4 inhibitors (0.79, 0.77 to 0.82). The three year absolute risk was 2.4% (95% CI 2.1% to 2.7%) lower for SGLT-2 inhibitors than DPP-4 inhibitors (4.6% v 7.0%), 1.8% (1.4% to 2.1%) lower...
DPP4I是一种基于肠促胰岛素的抗糖尿病药物,可抑制胰高糖素样肽1(GLP-1)的降解。DPP4I先前在一项回顾性队列研究中被证明可降低HCV感染患者的HCC风险7。根据Yamamoto等人的病例报告8,在DPP4I治疗4周后发现HCC自发消退。 SGLT2I vs DPP4I 这项基于人群的回顾性队列研究于2015年至2019年在香港进行,包括62699名...
SGLT-2抑制剂或GLP-1受体激动剂用于成人2型糖尿病.pdf,PRACTICE B For numbered affiliations see end of M RAPID RECOMMENDATIONS article. J : Correspondence to: R A Mustafa f i rmustafa@, Q Hao r SGLT-2 inhibitors or GLP-1 receptor agonists for adults with typ
SGLT2 inhibitors lower the risk of MACE in older age, despite smaller HbA1c reductions, while GLP-1 RAs were more cardioprotective in younger individuals with T2D.